E
Emmanuel Jouanneau
Researcher at French Institute of Health and Medical Research
Publications - 180
Citations - 4541
Emmanuel Jouanneau is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Pituitary tumors & Medicine. The author has an hindex of 30, co-authored 157 publications receiving 3601 citations. Previous affiliations of Emmanuel Jouanneau include Claude Bernard University Lyon 1 & University of Lyon.
Papers
More filters
Journal ArticleDOI
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
Jacqueline Trouillas,Jacqueline Trouillas,Pascal Roy,Nathalie Sturm,Emmanuelle Dantony,Christine Cortet-Rudelli,Gabriel Viennet,Jean-François Bonneville,Richard Assaker,Carole Auger,Carole Auger,Thierry Brue,Aurélie Cornelius,Henry Dufour,Emmanuel Jouanneau,Patrick François,Françoise Galland,François Mougel,François Chapuis,Laurent Villeneuve,Claude-Alain Maurage,Dominique Figarella-Branger,Gérald Raverot +22 more
TL;DR: A new, easy to use clinicopathological classification of pituitary endocrine tumours has demonstrated its prognostic worth by strongly predicting the probability of post-operative complete remission or tumour progression and so could help clinicians choose the best post-operation therapy.
Journal ArticleDOI
Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
Gérald Raverot,Nathalie Sturm,Florence de Fraipont,M. Muller,Sylvie Salenave,Philippe Caron,Olivier Chabre,Philippe Chanson,Christine Cortet-Rudelli,Richard Assaker,Henry Dufour,Stephan Gaillard,Patrick François,Emmanuel Jouanneau,Jean-Guy Passagia,Michèle Bernier,Aurélie Cornelius,Dominique Figarella-Branger,Jacqueline Trouillas,Françoise Borson-Chazot,Thierry Brue +20 more
TL;DR: In this paper, the authors describe the antitumoral efficacy and toxicity of temozolomide in patients with aggressive pituitary tumors or carcinomas and evaluate the possible prognostic value of MGMT promoter methylation and protein expression.
Journal ArticleDOI
Predicting Visual Outcome After Treatment of Pituitary Adenomas With Optical Coherence Tomography
Maud Jacob,Gérald Raverot,Gérald Raverot,Emmanuel Jouanneau,Emmanuel Jouanneau,Françoise Borson-Chazot,Françoise Borson-Chazot,Gilles Perrin,Muriel Rabilloud,Muriel Rabilloud,Caroline Tilikete,Caroline Tilikete,Martine Bernard,Alain Vighetto,Alain Vighetto +14 more
TL;DR: RNFL thinning measured by OCT puts the patient at decreased chance of recovery of an initial VF defect three months after treatment in pituitary adenomas compressing the anterior visual pathways.
Journal ArticleDOI
Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.
Gérald Raverot,Anne Wierinckx,Emmanuelle Dantony,Carole Auger,Guillaume Chapas,Laurent Villeneuve,Thierry Brue,Dominique Figarella-Branger,Pascal Roy,Emmanuel Jouanneau,Michel Jan,Joël Lachuer,Jacqueline Trouillas +12 more
TL;DR: This multiparameter investigation aimed to identify markers for recurrence and progression in prolactin tumors by retrospectively studying clinical data, tumor characteristics, clinical outcome, and the expression of nine genes by quantitative RT-PCR.
Journal ArticleDOI
Syringomyelia Associated with Type I Chiari Malformation A 21-Year Retrospective Study on 75 Cases Treated by Foramen Magnum Decompression with a Special Emphasis on the Value of Tonsils Resection
TL;DR: It is suggested that tonsils resection might enhance the results of FMD in individuals having Chiari I-related syringomyelia.